MBX
MBX Biosciences, Inc. Common StockMBX
MBX
About: MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.
Employees: 43
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
170% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 10
60% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 15
25% more funds holding
Funds holding: 63 [Q4 2024] → 79 (+16) [Q1 2025]
8.15% more ownership
Funds ownership: 98.57% [Q4 2024] → 106.72% (+8.15%) [Q1 2025]
57% less capital invested
Capital invested by funds: $606M [Q4 2024] → $263M (-$343M) [Q1 2025]
67% less funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 1 (-2) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$38
266%
upside
Avg. target
$41
295%
upside
High target
$44
324%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
JMP Securities Jonathan Wolleben | 266%upside $38 | Market Outperform Initiated | 10 Apr 2025 |
Guggenheim Seamus Fernandez | 324%upside $44 | Buy Reiterated | 10 Apr 2025 |
Financial journalist opinion
Based on 3 articles about MBX published over the past 30 days
Neutral
GlobeNewsWire
5 days ago
MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions
CARMEL, Ind., June 10, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced presentations at the American Diabetes Association's (ADA) 85th Scientific Sessions, taking place June 20-23. 2025, Chicago, IL.
Neutral
Seeking Alpha
2 weeks ago
MBX Biosciences: Consider Peptide Developer With GLP Drugs As A Speculative Buy
MBX Biosciences offers a unique prodrug approach with three promising candidates targeting hypoparathyroidism, post-bariatric hypoglycemia, and obesity - two of its three drug candidates are GLP receptor agonists. Upcoming Phase 2 data for canvuparatide in hypoparathyroidism is a major near-term catalyst, with limited competition and potential for multi-billion dollar peak sales. Despite early-stage risks, MBX's strong management, solid cash position, and differentiated pipeline make it a more attractive value proposition than many GLP-1 peers.
Neutral
GlobeNewsWire
3 weeks ago
MBX Biosciences to Participate in June Investor Conferences
CARMEL, Ind., May 20, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at and participate in the following investor conferences: Jefferies Global Healthcare Conference Dates: June 4-5, 2025Fireside Chat: June 4, 2025, 2:00 p.m.
Neutral
GlobeNewsWire
1 month ago
MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
Topline results for the Phase 2 Avail™ evaluating canvuparatide in patients with hypoparathyroidism expected in 3Q 2025 Investigational New Drug submission for MBX 4291 on track for 2Q 2025 $240.8 million in cash, cash equivalents and marketable securities as of March 31, 2025; expected to support operations into mid-2027 CARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today reported financial results for the first quarter ended March 31, 2025, and highlighted recent corporate progress.
Neutral
GlobeNewsWire
1 month ago
MBX Biosciences to Participate in Citizens and RBC May Investor Conferences
CARMEL, Ind., April 22, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at and participate in the Citizens Life Sciences Conference on May 7 and the RBC 2025 Global Healthcare Conference on May 21.
Neutral
GlobeNewsWire
2 months ago
MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference
CARMEL, Ind., March 26, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at and participate in the 24th Annual Needham Virtual Healthcare Conference.
Neutral
GlobeNewsWire
2 months ago
MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
Enrollment complete in Phase 2 Avail™ trial of canvuparatide in hypoparathyroidism; topline results on track for Q3 2025 MBX 1416 Phase 2 trial in patients with post-bariatric hypoglycemia expected to begin in 2H 2025 Investigational New Drug submission anticipated in Q2 2025 for MBX 4291 in obesity $262.1 million in cash, cash equivalents and marketable securities as of December 31, 2024; expected to support operations into mid-2027 CARMEL, Ind., March 17, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today reported financial results for the fourth quarter and full year ended December 31, 2024, and highlighted recent corporate progress.
Neutral
GlobeNewsWire
3 months ago
MBX Biosciences Announces Additions to Leadership Team
Chatan Charan, Ph.D. appointed as Senior Vice President, Pharmaceutical Development and CMC Mark Hope appointed as Senior Vice President, Regulatory and Quality CARMEL, Ind.
Neutral
GlobeNewsWire
3 months ago
MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism
CARMEL, Ind., March 03, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the completion of enrollment in its Phase 2 Avail™ trial of MBX 2109 (canvuparatide), the Company's parathyroid hormone (PTH) peptide prodrug.
Neutral
GlobeNewsWire
3 months ago
MBX Biosciences to Participate in March Investor Conferences
CARMEL, Ind., Feb. 18, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at and participate in the following investor conferences: TD Cowen 45th Annual Healthcare Conference Date: Monday, March 3, 2025Format: Podium Presentation and 1x1 meetingsTime: 10:30 a.m.
Charts implemented using Lightweight Charts™